Cooper Samantha, Spiro Stephen G
Department of Thoracic Medicine, University College Hospital, London, UK.
Respirology. 2006 May;11(3):241-8. doi: 10.1111/j.1440-1843.2006.00850.x.
Lung cancer was relatively uncommon at the turn of the 20th century, and has increased in prevalence at alarming rates, particularly because of the augmented trend in smoking, so that it is now the most common cause of cancer death in the world. As almost a quarter of these cancers are of small cell in origin, it seems only appropriate that small cell lung cancer receives ample attention, rather than seemingly to have been overlooked over the last 10-15 years. Despite its generally late presentation and high risk of dissemination, it is exceptionally sensitive to chemo-radiotherapy. This review looks at the diverse options of treatment that have been used over the last few years and tries to highlight the best available. As more than 50% of patients diagnosed with lung cancer are over 70 years of age and various studies have shown that older people respond just as well as their younger counterparts, with similar results in response rates, toxicity and outcomes, it is imperative that the older generation are not disregarded in terms of age being a contraindication to therapy.
肺癌在20世纪之交相对罕见，但其患病率以惊人的速度上升，尤其是由于吸烟趋势的增加，以至于它现在是世界上最常见的癌症死亡原因。由于几乎四分之一的这些癌症起源于小细胞，小细胞肺癌受到充分关注似乎是恰当的，而不是在过去10 - 15年里似乎被忽视了。尽管其通常出现较晚且扩散风险高，但它对放化疗异常敏感。本综述探讨了过去几年中使用的各种治疗选择，并试图突出最佳可用方案。由于超过50%被诊断为肺癌的患者年龄在70岁以上，并且各种研究表明老年人与年轻患者的反应一样好，在缓解率、毒性和结果方面有相似的结果，因此绝不能以年龄作为治疗禁忌而忽视老年一代。
